November 5, 2024 12:14 PM ESTUpdated November 6, 07:47 AM
R&D

J&J's Darza­lex hits pri­ma­ry end­point in Phase 3 ear­ly-stage mul­ti­ple myelo­ma tri­al

Katherine Lewin

News Reporter

John­son & John­son’s CD38 in­hibitor Darza­lex showed a ben­e­fit in de­lay­ing or pre­vent­ing dis­ease pro­gres­sion in pa­tients with high-risk smol­der­ing mul­ti­ple myelo­ma, a pre­cur­sor to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times